InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: davidal66 post# 406

Monday, 08/15/2016 7:49:05 PM

Monday, August 15, 2016 7:49:05 PM

Post# of 2099
Two things I took away from the conf call:

1) Ovarian: "Additionally, 52% of the patient had tumors and had failed respond to prior anti-angiogenic agents including Avastin. Practically, most patients in Phase II trials has a better prognosis making this already a late trial. So while we design the trial primarily to look at safety, we were happy to see such significant efficacy."

2) RGBM: "We are saying that we are according to plan, but actually we are ahead of plan, but wanted to be very careful, because it goes month-by-month, but right now the excitement around the trial is quite big and we are recruiting very well."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News